NEW YORK (GenomeWeb News) – Affymetrix said today that Medical Prognosis Institute, a cancer diagnostic firm based in Denmark, will use the Affy microarray platform to develop drug sensitivity prediction and prognostic tools for patients with cancer.
 
Under the terms of the “Powered by Affymetrix” agreement, MPI gains non-exclusive access to Affy’s technology to develop and commercialize tools that will identify patients likely to respond to anti-cancer drugs.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.